GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
DE60112609T2
(de)
|
2000-12-15 |
2006-01-19 |
Glaxo Group Ltd., Greenford |
Pyrazolopyridine
|
AU2002239348A1
(en)
|
2000-12-15 |
2002-06-24 |
Glaxo Group Limited |
Pyrazolopyridine derivatives
|
EP1366048B1
(en)
|
2001-03-08 |
2004-08-25 |
SmithKline Beecham Corporation |
Pyrazolopyridine derivatives
|
EP1372643A1
(en)
|
2001-03-30 |
2004-01-02 |
Smithkline Beecham Corporation |
Pyrazolopyridines, process for their preparation and use as therapeutic compounds
|
EP1377575B1
(en)
|
2001-04-10 |
2006-07-05 |
SmithKline Beecham Corporation |
Antiviral pyrazolopyridine compounds
|
JP2004527560A
(ja)
|
2001-04-27 |
2004-09-09 |
スミスクライン ビーチャム コーポレーション |
ピラゾロ[1,5−α]ピリジン誘導体
|
US6756498B2
(en)
|
2001-04-27 |
2004-06-29 |
Smithkline Beecham Corporation |
Process for the preparation of chemical compounds
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
CA2451008A1
(en)
|
2001-06-21 |
2003-01-03 |
Smithkline Beecham Corporation |
Imidazo[1,2-a!pyridine derivatives for the prophylaxis and treatment of herpes viral infections
|
ES2262893T3
(es)
|
2001-10-05 |
2006-12-01 |
Smithkline Beecham Corporation |
Derivados de imidazo-piridina para su uso en el tratamiento de infeccion virica por herpes.
|
ES2292839T3
(es)
|
2001-12-11 |
2008-03-16 |
Smithkline Beecham Corporation |
Derivados de pirazolo-piridina como agentes contra el herpes.
|
ATE323706T1
(de)
|
2001-12-17 |
2006-05-15 |
Smithkline Beecham Corp |
Pyrazolopyridazinderivate
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
DE60301339T2
(de)
|
2002-03-07 |
2006-03-09 |
Smithkline Beecham Corp. |
Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
|
GB0205688D0
(en)
*
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
WO2003076434A1
(en)
|
2002-03-09 |
2003-09-18 |
Astrazeneca Ab |
4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
|
DE60314623T2
(de)
|
2002-05-10 |
2008-02-28 |
Smithkline Beecham Corp. |
Substituierte pyrazolopyrimidine
|
WO2004022562A1
(en)
|
2002-09-09 |
2004-03-18 |
Cellular Genomics, Inc. |
6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
|
EP1546148A1
(en)
|
2002-10-03 |
2005-06-29 |
SmithKline Beecham Corporation |
Therapeutic compounds based on pyrazolopyridine derivatives
|
US7160885B2
(en)
|
2003-02-10 |
2007-01-09 |
Cgi Pharmaceuticals, Inc. |
Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
|
RS20050810A
(en)
|
2003-04-29 |
2007-08-03 |
Pfizer Inc., |
5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
WO2005014599A1
(en)
|
2003-06-04 |
2005-02-17 |
Cellular Genomics, Inc. |
Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
|
US8178671B2
(en)
|
2003-07-30 |
2012-05-15 |
Rigel Pharmaceuticals, Inc. |
Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
|
WO2005019220A2
(en)
*
|
2003-08-11 |
2005-03-03 |
Cellular Genomics Inc. |
Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
WO2005097799A1
(en)
|
2004-04-07 |
2005-10-20 |
Pfizer Limited |
Pyrazolo`4,3-d! pyrimidines
|
AR051387A1
(es)
|
2004-10-13 |
2007-01-10 |
Wyeth Corp |
Analogos de anilino-pirimidina
|
WO2006050076A1
(en)
*
|
2004-10-29 |
2006-05-11 |
Janssen Pharmaceutica, N.V. |
Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
|
ZA200704476B
(en)
|
2004-11-04 |
2008-09-25 |
Vertex Pharma |
Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
|
CA2589793A1
(en)
*
|
2004-12-17 |
2006-06-22 |
Astrazeneca Ab |
4-(4-(imidazol-4-yl)pyrimidin-2-ylamino) benzamides as cdk inhibitors
|
DE602006010979D1
(de)
|
2005-01-19 |
2010-01-21 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
WO2007024294A2
(en)
|
2005-05-03 |
2007-03-01 |
Cgi Pharmaceuticals, Inc. |
Certain substituted ureas, as modulators of kinase activity
|
EP1904457B1
(en)
|
2005-06-08 |
2017-09-06 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
EP1912974A1
(en)
*
|
2005-07-30 |
2008-04-23 |
AstraZeneca AB |
Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
|
US7750000B2
(en)
|
2005-09-02 |
2010-07-06 |
Bayer Schering Pharma Ag |
Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
|
DE102005042742A1
(de)
*
|
2005-09-02 |
2007-03-08 |
Schering Ag |
Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
US7723336B2
(en)
|
2005-09-22 |
2010-05-25 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful as kinase modulators
|
EP1934213A1
(en)
*
|
2005-09-30 |
2008-06-25 |
Astra Zeneca AB |
Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
|
TW200811169A
(en)
*
|
2006-05-26 |
2008-03-01 |
Astrazeneca Ab |
Chemical compounds
|
DE102006029447A1
(de)
*
|
2006-06-21 |
2007-12-27 |
Bayer Schering Pharma Ag |
Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
|
PT2044025E
(pt)
|
2006-06-30 |
2012-12-17 |
Novartis Ag |
Derivados de quinolinona e suas composições farmacêuticas
|
EP2063962A2
(en)
*
|
2006-09-07 |
2009-06-03 |
Biogen Idec MA Inc. |
Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
|
AR063946A1
(es)
*
|
2006-09-11 |
2009-03-04 |
Cgi Pharmaceuticals Inc |
Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
|
PL2099447T3
(pl)
|
2006-11-22 |
2013-06-28 |
Incyte Holdings Corp |
Imidazotriazyny i imidazopirmidyny jako inhibitory kinaz
|
RU2493155C2
(ru)
*
|
2006-12-08 |
2013-09-20 |
Ф.Хоффманн-Ля Рош Аг |
Замещенные пиримидины и их применение в качестве модуляторов jnk
|
AR064420A1
(es)
*
|
2006-12-21 |
2009-04-01 |
Alcon Mfg Ltd |
Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
|
JP5442449B2
(ja)
|
2006-12-22 |
2014-03-12 |
アステックス、セラピューティックス、リミテッド |
新規化合物
|
AR064491A1
(es)
|
2006-12-22 |
2009-04-08 |
Astex Therapeutics Ltd |
Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr.
|
FR2918061B1
(fr)
|
2007-06-28 |
2010-10-22 |
Sanofi Aventis |
Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
|
US8143253B2
(en)
*
|
2007-07-26 |
2012-03-27 |
Novartis Ag |
Organic compounds
|
GB0720038D0
(en)
|
2007-10-12 |
2007-11-21 |
Astex Therapeutics Ltd |
New compounds
|
GB0720041D0
(en)
|
2007-10-12 |
2007-11-21 |
Astex Therapeutics Ltd |
New Compounds
|
WO2009060197A1
(en)
*
|
2007-11-08 |
2009-05-14 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Imidazopyridazines for use as protein kinase inhibitors
|
US8067409B2
(en)
|
2007-11-27 |
2011-11-29 |
Abbott Laboratories |
Protein kinase inhibitors
|
NZ586662A
(en)
|
2007-12-19 |
2012-08-31 |
Vertex Pharma |
PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JANUS KINASE 2 INHIBITORS
|
US20100331333A1
(en)
*
|
2007-12-21 |
2010-12-30 |
Wyeth Llc |
Imidazo [1,2-B] Pyridazine Compounds
|
JP5394404B2
(ja)
|
2008-02-06 |
2014-01-22 |
ブリストル−マイヤーズ スクイブ カンパニー |
キナーゼ阻害剤として有用な置換イミダゾピリダジン類
|
WO2009102468A1
(en)
|
2008-02-13 |
2009-08-20 |
Cgi Pharmaceuticals, Inc. |
6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
|
GB0810902D0
(en)
|
2008-06-13 |
2008-07-23 |
Astex Therapeutics Ltd |
New compounds
|
WO2010002985A1
(en)
*
|
2008-07-01 |
2010-01-07 |
Ptc Therapeutics, Inc. |
Bmi-1 protein expression modulators
|
EP2303841A1
(en)
|
2008-07-14 |
2011-04-06 |
Gilead Sciences, Inc. |
Oxindolyl inhibitor compounds
|
NZ590283A
(en)
|
2008-07-14 |
2012-11-30 |
Gilead Sciences Inc |
Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
|
WO2010009155A2
(en)
*
|
2008-07-14 |
2010-01-21 |
Gilead Colorado, Inc. |
Fused heterocyclyc inhibitor compounds
|
EP2326622A1
(en)
|
2008-07-28 |
2011-06-01 |
Gilead Sciences, Inc. |
Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
|
US8450321B2
(en)
|
2008-12-08 |
2013-05-28 |
Gilead Connecticut, Inc. |
6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
|
CN104744476B
(zh)
|
2008-12-08 |
2017-04-12 |
吉利德康涅狄格公司 |
咪唑并吡嗪syk抑制剂
|
CN104059073B
(zh)
|
2008-12-08 |
2017-04-12 |
吉利德康涅狄格公司 |
咪唑并哌嗪syk抑制剂
|
GB0906470D0
(en)
|
2009-04-15 |
2009-05-20 |
Astex Therapeutics Ltd |
New compounds
|
GB0906472D0
(en)
|
2009-04-15 |
2009-05-20 |
Astex Therapeutics Ltd |
New compounds
|
AU2010259042A1
(en)
|
2009-06-08 |
2011-12-15 |
Gilead Sciences, Inc. |
Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
|
US8258316B2
(en)
|
2009-06-08 |
2012-09-04 |
Gilead Sciences, Inc. |
Alkanoylamino benzamide aniline HDAC inhibitor compounds
|
ES2651296T3
(es)
|
2009-10-30 |
2018-01-25 |
Janssen Pharmaceutica, N.V. |
Derivados de imidazo[1,2-b]piridacina y su uso como inhibidores de PDE10
|
AR080754A1
(es)
|
2010-03-09 |
2012-05-09 |
Janssen Pharmaceutica Nv |
Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
|
KR101717809B1
(ko)
|
2010-03-11 |
2017-03-17 |
질레드 코네티컷 인코포레이티드 |
이미다조피리딘 syk 억제제
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
CN103476759B
(zh)
|
2011-04-19 |
2016-03-16 |
拜耳知识产权有限责任公司 |
取代的4-芳基-n-苯基-1,3,5-三嗪-2-胺
|
TW201636330A
(zh)
|
2011-05-24 |
2016-10-16 |
拜耳知識產權公司 |
含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
|
US20120302573A1
(en)
|
2011-05-25 |
2012-11-29 |
Paul Francis Jackson |
Methods of inhibiting pro matrix metalloproteinase activation
|
EP2723746A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
WO2013000924A1
(en)
|
2011-06-27 |
2013-01-03 |
Janssen Pharmaceutica Nv |
1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
|
EP2755956B1
(en)
|
2011-09-16 |
2016-05-18 |
Bayer Intellectual Property GmbH |
2,4-disubstituted 5-fluoro-pyrimidines as selective cdk9 inhibtors
|
EP2755948B1
(en)
|
2011-09-16 |
2016-05-25 |
Bayer Intellectual Property GmbH |
Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
|
ME03300B
(me)
|
2012-06-13 |
2019-07-20 |
Incyte Holdings Corp |
Supsтituisana triciklična jedinjenja као inhibiтori fgfr
|
EP2863909B1
(en)
|
2012-06-26 |
2020-11-04 |
Janssen Pharmaceutica N.V. |
Combinations comprising 4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline compounds as pde 2 inhibitors and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
|
CN104411314B
(zh)
|
2012-07-09 |
2017-10-20 |
詹森药业有限公司 |
磷酸二酯酶10的抑制剂
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
ES2597232T3
(es)
|
2012-10-18 |
2017-01-17 |
Bayer Pharma Aktiengesellschaft |
4-(orto)-fluorofenil-5-fluoropirimidin-2-il aminas que contienen un grupo sulfona
|
US9670161B2
(en)
|
2012-10-18 |
2017-06-06 |
Bayer Pharma Aktiengesellschaft |
5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
|
TW201418243A
(zh)
|
2012-11-15 |
2014-05-16 |
Bayer Pharma AG |
含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
|
PE20151413A1
(es)
|
2012-11-21 |
2015-10-23 |
Ptc Therapeutics Inc |
Inhibidores de bmi-1 de pirimidina inversa sustituida
|
CN107501275B
(zh)
|
2012-12-07 |
2019-11-22 |
沃泰克斯药物股份有限公司 |
可用作atr激酶抑制剂的化合物
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
EP2970286A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Inc. |
Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
|
WO2014143242A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
EP2970289A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
ES2657451T3
(es)
|
2013-04-19 |
2018-03-05 |
Incyte Holdings Corporation |
Heterocíclicos bicíclicos como inhibidores del FGFR
|
SI3027171T1
(sl)
|
2013-07-30 |
2020-08-31 |
Gilead Connecticut, Inc. |
Formulacija inhibitorjev SYK
|
ES2822285T3
(es)
|
2013-07-30 |
2021-04-30 |
Kronos Bio Inc |
Polimorfo de inhibidores de SYK
|
JP6524094B2
(ja)
|
2013-08-30 |
2019-06-05 |
ピーティーシー セラピューティクス, インコーポレイテッド |
置換ピリミジンBmi−1阻害剤
|
MY184733A
(en)
|
2013-10-18 |
2021-04-20 |
Eisai R&D Man Co Ltd |
Pyrimidine fgfr4 inhibitors
|
US10584115B2
(en)
|
2013-11-21 |
2020-03-10 |
Ptc Therapeutics, Inc. |
Substituted pyridine and pyrazine BMI-1 inhibitors
|
KR20180002888A
(ko)
|
2013-12-04 |
2018-01-08 |
길리애드 사이언시즈, 인코포레이티드 |
암을 치료하는 방법
|
RU2720408C2
(ru)
|
2013-12-06 |
2020-04-29 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ получения ингибиторов atr киназы (варианты)
|
US9290505B2
(en)
|
2013-12-23 |
2016-03-22 |
Gilead Sciences, Inc. |
Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
|
UY35898A
(es)
|
2013-12-23 |
2015-07-31 |
Gilead Sciences Inc |
?compuestos inhibidores de syk y composiciones que los comprenden?.
|
AU2015271030B2
(en)
|
2014-06-05 |
2019-05-16 |
Vertex Pharmaceuticals Incorporated |
Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof
|
ES2733847T3
(es)
|
2014-06-17 |
2019-12-03 |
Vertex Pharma |
Método para tratar cáncer usando una combinación de inhibidores de CHK1 y ATR
|
BR112016028641A2
(pt)
|
2014-07-14 |
2017-08-22 |
Gilead Sciences Inc |
?método para tratar câncer?
|
EP3207037B1
(en)
|
2014-10-16 |
2019-01-23 |
Bayer Pharma Aktiengesellschaft |
Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
ES2751669T3
(es)
|
2015-02-20 |
2020-04-01 |
Incyte Corp |
Heterociclos bicíclicos como inhibidores FGFR
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
EP3274338A1
(en)
|
2015-03-24 |
2018-01-31 |
Bayer Pharma Aktiengesellschaft |
Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma
|
WO2016150902A1
(en)
|
2015-03-24 |
2016-09-29 |
Bayer Pharma Aktiengesellschaft |
Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers
|
CA2980507A1
(en)
|
2015-03-24 |
2016-09-29 |
Public University Corporation Nagoya City University |
Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating lymphomas
|
CN108290903B
(zh)
|
2015-09-29 |
2021-09-03 |
拜耳医药股份有限公司 |
新的大环磺酰二亚胺化合物
|
WO2017059357A1
(en)
|
2015-09-30 |
2017-04-06 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of dna damaging agents and atr inhibitors
|
JP6888000B2
(ja)
|
2015-10-08 |
2021-06-16 |
バイエル ファーマ アクチエンゲゼルシャフト |
新規な修飾された大環状化合物
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
WO2018013430A2
(en)
|
2016-07-12 |
2018-01-18 |
Arisan Therapeutics Inc. |
Heterocyclic compounds for the treatment of arenavirus infection
|
KR20180088113A
(ko)
*
|
2017-01-26 |
2018-08-03 |
한미약품 주식회사 |
이미다조피리다진 화합물
|
PL3601253T3
(pl)
|
2017-03-28 |
2022-01-17 |
Bayer Aktiengesellschaft |
Nowe hamujące ptefb związki makrocykliczne
|
CA3057891A1
(en)
|
2017-03-28 |
2018-10-04 |
Bayer Aktiengesellschaft |
Novel ptefb inhibiting macrocyclic compounds
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
CA3073871A1
(en)
|
2017-08-25 |
2019-02-28 |
Gilead Sciences, Inc. |
Polymorphs of syk inhibitors
|
CN111683976B
(zh)
|
2018-02-05 |
2022-11-18 |
生物辐射实验室股份有限公司 |
具有阴离子交换-疏水混合模式配体的色谱树脂
|
KR20200119800A
(ko)
|
2018-02-13 |
2020-10-20 |
바이엘 악티엔게젤샤프트 |
미만성 거대 b-세포 림프종을 치료하기 위한 5-플루오로-4-(4-플루오로-2-메톡시페닐)-n-[4-[(s-메틸술폰이미도일)메틸]피리딘-2-일]피리딘-2-아민의 용도
|
JP2021523118A
(ja)
|
2018-05-04 |
2021-09-02 |
インサイト・コーポレイションIncyte Corporation |
Fgfr阻害剤の塩
|
CR20200590A
(es)
|
2018-05-04 |
2021-04-26 |
Incyte Corp |
Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
CN113950479A
(zh)
|
2019-02-22 |
2022-01-18 |
克洛诺斯生物股份有限公司 |
作为syk抑制剂的缩合吡嗪的固体形式
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
CR20220066A
(es)
|
2019-08-14 |
2022-11-28 |
Incyte Corp |
Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
|
CN115298177A
(zh)
|
2019-10-11 |
2022-11-04 |
因赛特公司 |
作为cdk2抑制剂的双环胺
|
IL291901A
(en)
|
2019-10-14 |
2022-06-01 |
Incyte Corp |
Bicyclyl heterocycles as fgr suppressors
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
JP2023505257A
(ja)
|
2019-12-04 |
2023-02-08 |
インサイト・コーポレイション |
Fgfr阻害剤の誘導体
|
JP2023505258A
(ja)
|
2019-12-04 |
2023-02-08 |
インサイト・コーポレイション |
Fgfr阻害剤としての三環式複素環
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|